A Phase I Study for Safety and Tolerability of AL002.

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

August 3, 2020

Study Completion Date

November 25, 2020

Conditions
HealthyAlzheimer Disease
Interventions
BIOLOGICAL

AL002

Single-doses of AL002 in up to 9 dose-escalating cohorts

OTHER

Saline Solution

Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients

Trial Locations (6)

10032

Columbia University, New York

32162

Compass Research - The Villages, The Villages

32806

Compass Research - Orlando, Orlando

33445

Brain Matters Research, Delray Beach

Unknown

Nucleus Network Pty Ltd, Melbourne

University College London, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alector Inc.

INDUSTRY